Glioblastoma chemotherapy
In 2005, a prospective, randomized, phase 3 trial by the European Organization for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) reported improved progression-free and overall survival for patients with Glioblastoma with the addition of concomitant and adjuvant temozolomide (TMZ), an oral alkylating agent, to radiotherapy (RT) following maximal safe resection 1).
1)
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987–96.10.1056/NEJMoa043330